What is Onco Aura, Dispositif Spécifique Régional Du Cancer's official website?

Onco Aura, Dispositif Spécifique Régional Du Cancer's website is onco-aura.fr

How many employees are working in Onco Aura, Dispositif Spécifique Régional Du Cancer right now?

Onco Aura, Dispositif Spécifique Régional Du Cancer has 17 employees.

Who are Onco Aura, Dispositif Spécifique Régional Du Cancer's top competitors?

Onco Aura, Dispositif Spécifique Régional Du Cancer's top competitors are , , , , , ,

Onco Aura, Dispositif Spécifique Régional Du Cancer company information, Employees & Contact Information

Q: What is Onco Aura, Dispositif Spécifique Régional Du Cancer's industry?

Onco Aura, Dispositif Spécifique Régional Du Cancer's industry is Civic and Social Organizations

Updated May 2026

Quick answer

Onco Aura, Dispositif Spécifique Régional Du Cancer is a Civic and Social Organizations company. It has approximately 17 employees on record. Contact data was last refreshed in May 2026. Find Onco Aura, Dispositif Spécifique Régional Du Cancer's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Explore related pages

Onco Aura, Dispositif Spécifique Régional Du Cancer email format Onco Aura, Dispositif Spécifique Régional Du Cancer management contacts

Related company profiles:

Plusieurs missions sont confiées au Dispositif Spécifique Régional du Cancer Auvergne-Rhône-Alpes : - Contribuer à la coordination de l’organisation régionale de l’offre de soins en cancérologie et à sa lisibilité. - Promouvoir la qualité et la sécurité des traitements des patients atteints de cancer. - Développer l’expertise et l’expérimentation de projets communs innovants et accompagner les évolutions de l’offre de soins. - Contribuer à l’information et à la formation des acteurs, des patients et de leurs proches sur le parcours de santé en cancérologie.

Employees: 17
Address: 60, Avenue Rockefeller, Lyon,auvergne-Rhône-Alpes 69008,france
Industry: Civic And Social Organizations
NAICS: Civic and Social Organizations
Website: onco-aura.fr
Keywords: et l’expérimentation de projets communs innovants et accompagner les évolutions de l’offre de soins..
HQ: Lyon, Auvergne-Rhône-Alpes
Competitors: SFC - Société Française du Cancer, Centre Léon Bérard, ONCOPL Dispositif spécifique régional du cancer, DSRC_GrandEst_NEON, Onco-Occitanie, Onco-Nouvelle-Aquitaine, oncoBFC- Dispositif Spécifique Régional du Cancer de Bourgogne-Franche-Comté, Institut national du cancer, ONCORIF - Dispositif Spécifique Régional du Cancer en Île-de-France, Dispositif Spécifique Régional du Cancer OncoPaca-Corse.

Onco Aura, Dispositif Spécifique Régional Du Cancer Questions

News

FDA Approval of INLEXZO for BCG-Unresponsive Bladder Cancer - Oncodaily

FDA Approval of INLEXZO for BCG-Unresponsive Bladder Cancer Oncodaily

12 new breakthroughs in the fight against cancer - The World Economic Forum

12 new breakthroughs in the fight against cancer The World Economic Forum

Does Sunscreen Cause Cancer? Myths and Facts - Oncodaily

Does Sunscreen Cause Cancer? Myths and Facts Oncodaily

ONCAURA WELLNESS CENTER OFFICIALLY LAUNCHED IN MANZINI, PIONEERING HOLISTIC CANCER CARE IN ESWATINI - Eswatini Positive News

ONCAURA WELLNESS CENTER OFFICIALLY LAUNCHED IN MANZINI, PIONEERING HOLISTIC CANCER CARE IN ESWATINI Eswatini Positive News

PLK1 in cancer therapy: a comprehensive review of immunomodulatory mechanisms and therapeutic opportunities - Frontiers

PLK1 in cancer therapy: a comprehensive review of immunomodulatory mechanisms and therapeutic opportunities Frontiers

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance - Journal of Hematology & Oncology

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance Journal of Hematology & Oncology

The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies - ScienceDirect.com

The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies ScienceDirect.com

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer | British Journal of Cancer - Nature

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer | British Journal of Cancer Nature

Breast cancer: New blood test can predict return, researchers say - BBC

Breast cancer: New blood test can predict return, researchers say BBC

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer - The New England Journal of Medicine

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer The New England Journal of Medicine

Exploring the anti-cancer potential of dietary phytochemicals for the patients with breast cancer: A comprehensive review - Wiley Online Library

Exploring the anti-cancer potential of dietary phytochemicals for the patients with breast cancer: A comprehensive review Wiley Online Library

Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis - Frontiers

Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis Frontiers

A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer - ScienceDirect.com

A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer ScienceDirect.com

Moving Breast Cancer Therapy up a Notch - Frontiers

Moving Breast Cancer Therapy up a Notch Frontiers

Sabine Brookman-May joins Aura Biosciences as Therapeutic Area Head, Urologic Oncology - Oncodaily

Sabine Brookman-May joins Aura Biosciences as Therapeutic Area Head, Urologic Oncology Oncodaily

Liposome-based diagnostic and therapeutic applications for pancreatic cancer - ScienceDirect.com

Liposome-based diagnostic and therapeutic applications for pancreatic cancer ScienceDirect.com

Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review - Frontiers

Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review Frontiers

Early results from a Phase 1 trial of Aura Biosciences drug bel-sar (AU-011) - Oncodaily

Early results from a Phase 1 trial of Aura Biosciences drug bel-sar (AU-011) Oncodaily

ctDNA as a cancer biomarker: A broad overview - ScienceDirect.com

ctDNA as a cancer biomarker: A broad overview ScienceDirect.com

Cholesterol in the ciliary membrane as a therapeutic target against cancer - Frontiers

Cholesterol in the ciliary membrane as a therapeutic target against cancer Frontiers

Molecular Profiling–Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges - Frontiers

Molecular Profiling–Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges Frontiers

Emerging therapies for non-small cell lung cancer - Journal of Hematology & Oncology

Emerging therapies for non-small cell lung cancer Journal of Hematology & Oncology

The anti-cancer effectiveness of some heterocyclic compounds containing sulfur atom - ScienceDirect.com

The anti-cancer effectiveness of some heterocyclic compounds containing sulfur atom ScienceDirect.com

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study - The Lancet

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study The Lancet

Localising BRCA gene mutations to better treat ovarian cancer - Institut Curie - Espace presse

Localising BRCA gene mutations to better treat ovarian cancer Institut Curie - Espace presse

Companies like Onco Aura, Dispositif Spécifique Régional Du Cancer

Top Onco Aura, Dispositif Spécifique Régional Du Cancer Employees

Morgane Le Guienne

Chargée De Communication - Dispositif…

N/a

View
Clément LEVY

Directeur Général Chez Hôpital Privé…

N/a

View
pierre ROCCAMATISI

Responsable Système D'Information

Greater Lyon Area, France

View

2
actibase.fr, novealis.com
Morgane Abel

Psychologue Libéral-Hypnothérapeute

Greater Lyon Area, France

View

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles

Get direct phone numbers & mobile contacts

Access company data & employee information

Works directly on LinkedIn - no copy/paste needed

Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Learn More

How It Works

Get a Free Account

Search the #1 Contact Database

Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.

Use our AI-Powered Email Finder

Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.

Have a look at Aeroleads Data

Browse our Data

Company Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Profile Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

List Search

a b c d e f g h i j k l m n o p q r s t u v w x y z

Onco Aura, Dispositif Spécifique Régional Du Cancer company information, Employees & Contact Information

Quick answer

Explore related pages

Company Details

Onco Aura, Dispositif Spécifique Régional Du Cancer Questions

What is Onco Aura, Dispositif Spécifique Régional Du Cancer's official website?

What is Onco Aura, Dispositif Spécifique Régional Du Cancer's LinkedIn profile?

How many employees are working in Onco Aura, Dispositif Spécifique Régional Du Cancer right now?

What is Onco Aura, Dispositif Spécifique Régional Du Cancer's industry?

What are Onco Aura, Dispositif Spécifique Régional Du Cancer's top competitors?

What are Onco Aura, Dispositif Spécifique Régional Du Cancer's categories?

News

FDA Approval of INLEXZO for BCG-Unresponsive Bladder Cancer - Oncodaily

12 new breakthroughs in the fight against cancer - The World Economic Forum

Does Sunscreen Cause Cancer? Myths and Facts - Oncodaily

ONCAURA WELLNESS CENTER OFFICIALLY LAUNCHED IN MANZINI, PIONEERING HOLISTIC CANCER CARE IN ESWATINI - Eswatini Positive News

PLK1 in cancer therapy: a comprehensive review of immunomodulatory mechanisms and therapeutic opportunities - Frontiers

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance - Journal of Hematology & Oncology

The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies - ScienceDirect.com

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer | British Journal of Cancer - Nature

Breast cancer: New blood test can predict return, researchers say - BBC

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer - The New England Journal of Medicine

Exploring the anti-cancer potential of dietary phytochemicals for the patients with breast cancer: A comprehensive review - Wiley Online Library

Comparing Biomarkers for Predicting Pathological Responses to Neoadjuvant Therapy in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis - Frontiers

A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer - ScienceDirect.com

Moving Breast Cancer Therapy up a Notch - Frontiers

Sabine Brookman-May joins Aura Biosciences as Therapeutic Area Head, Urologic Oncology - Oncodaily

Liposome-based diagnostic and therapeutic applications for pancreatic cancer - ScienceDirect.com

Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review - Frontiers

Early results from a Phase 1 trial of Aura Biosciences drug bel-sar (AU-011) - Oncodaily

ctDNA as a cancer biomarker: A broad overview - ScienceDirect.com

Cholesterol in the ciliary membrane as a therapeutic target against cancer - Frontiers

Molecular Profiling–Based Precision Medicine in Cancer: A Review of Current Evidence and Challenges - Frontiers

Emerging therapies for non-small cell lung cancer - Journal of Hematology & Oncology

The anti-cancer effectiveness of some heterocyclic compounds containing sulfur atom - ScienceDirect.com

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study - The Lancet

Localising BRCA gene mutations to better treat ovarian cancer - Institut Curie - Espace presse

Companies like Onco Aura, Dispositif Spécifique Régional Du Cancer

Dsrc_Grandest_Neon

Sfc - Société França...

Dispositif Spécifiqu...

Onco-Nouvelle-Aquitaine

Oncopl Dispositif Sp...

Oncobfc- Dispositif ...

Centre Léon Bérard

Institut National Du...

Oncorif - Dispositif...

Onco-Occitanie

Top Onco Aura, Dispositif Spécifique Régional Du Cancer Employees

Morgane Le Guienne

Chargée De Communication - Dispositif…

Clément LEVY

Directeur Général Chez Hôpital Privé…

pierre ROCCAMATISI

Responsable Système D'Information

Morgane Abel

Psychologue Libéral-Hypnothérapeute

Free Chrome Extension

Aero Online

Select data to include:

How It Works

Get a Free Account

Search the #1 Contact Database

Use our AI-Powered Email Finder

Have a look at Aeroleads Data